Astellas to showcase late stage oncology portfolio at ASCO 2026 with long term follow up data

Astellas Pharma has confirmed it will roll out 10 abstracts — including two oral presentations — across its oncology portfolio at the 2026 American Society of Clinical Oncology Annual Meeting, running 29 May to 2 June in Chicago. The line-up leans heavily on longer-term follow-up and real-world clinical use, fleshing out how its established regimens hold up over time and across patient subgroups.

In urothelial cancer, the standout will be a 3.5-year follow-up from the Phase 3 EV-302 study (also referred to as KEYNOTE-A39), which is testing enfortumab vedotin alongside pembrolizumab as a first-line option in locally advanced or metastatic disease. The update is intended to sharpen the picture on how durable the regimen’s benefit is in advanced settings — a key consideration as clinicians weigh sequencing decisions. Astellas will round out the urothelial program with multiple readouts exploring the same combination in earlier-stage disease, building out a broader evidence base for use across the treatment continuum and across patient subpopulations.

In advanced prostate cancer, the company will present additional analyses from its established programs in non-metastatic hormone- (or castration-) sensitive disease with high-risk biochemical recurrence and in metastatic hormone-sensitive disease, including the EMBARK and ARCHES studies. The new cuts are designed to flesh out how outcomes track across patients with differing clinical profiles and inform treatment selection in everyday practice.

The company will also use ASCO to make its first appearance at the meeting in women’s health, with a trial-in-progress update on HIGHLIGHT 1. That study is evaluating fezolinetant for moderate to severe vasomotor symptoms in women with stage 0–3 hormone receptor-positive breast cancer who are on adjuvant endocrine therapy. Fezolinetant’s safety and efficacy in this group have not yet been established; the agent is currently approved by the US Food and Drug Administration for moderate to severe vasomotor symptoms due to menopause.

Among the enfortumab vedotin presentations, T. Powles will deliver the EV-302 3.5-year follow-up and response analysis in an oral session (abstract 4507) on 29 May. P. O’Donnell will give an oral presentation on health-related quality of life from the Phase 3 KEYNOTE-905 study of neoadjuvant and adjuvant enfortumab vedotin plus pembrolizumab in cisplatin-ineligible muscle-invasive bladder cancer (abstract 4510) on 30 May. Two poster presentations on 31 May will round out the muscle-invasive bladder cancer data: N. Adra on clinically relevant subgroup analyses from KEYNOTE-905 (abstract 4613), and C. Hoimes on exploratory subgroup outcomes from the cisplatin-eligible KEYNOTE-B15 study (abstract 4614).

---

---

Related Topics and Keywords

asco2026, Astellas, Astellas Pharma, oncology portfolio